Navigation Links
Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM)
Date:10/17/2007

g lesions (greater than 20 mm). Target vessel failure is defined as cardiac death, myocardial infarction or repeat vascularization of a treated vessel.

Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company.

For more information about TRIAS, call +31.20.56.67.883 or send an e-mail to trias@amc.nl.


'/>"/>
SOURCE Academic Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... America commands the vital signs monitoring devices ... Europe . The North American and European ... million and $907.0 million, respectively, by the end of ... to the rising number of elderly people across these ... boost in demand owing to the rising demand for ...
(Date:9/2/2014)... 2014  XBiotech announced today interim results from ... the US for its anti-cancer agent Xilonix™. ... is being evaluated in advanced colorectal cancer patients ... primary endpoint of the study is overall survival, ... control population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... und CALGARY, Alberta , September 2, ... in der "State of the Art and Featured Research ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, dass ... Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 in ... hat. In seinem Vortrag mit dem Titel " Effects ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... September 03, 2014 Operators in the ... millions of people annually, arranging care and counsel for ... private enterprises are expected to derive $39.4 billion in ... and private income. Over the five years through 2014-15, ... rate of 6.6%, including growth of 4.1% in 2014-15. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... new studies further confirm the health benefits of breast-feeding. ... a lower risk of ear, throat and sinus infections ... similar trend when it comes to allergies. The ... immediate newborn period," said Dr. Jennifer Wu, an obstetrician-gynecologist ... was not involved in the new studies. The ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: